Cambridge Antibody Technology Group plc Company Profile

12:00 EDT 22nd March 2018 | BioPortfolio

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the characteristics of antibodies both to discover and validate new disease targets and to develop human monoclonal antibodies as new treatments for disease.


The Science Park
United Kingdom


Phone: +44 (0) 1763 263 233
Fax: +44 (0) 1763 263 413

News Articles [1428 Associated News Articles listed on BioPortfolio]

New Rabbit Monclonal Antibody to Group B Streptococcus

New antibody reacts with the GBS Lancefield carbohydrate antigen found on the surface of the bacterium

Cambridge Analytica Suspends CEO After Alarming Reports On Its Election Maneuvers

Cambridge Analytica, the British political research group linked to President

Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The ...

RESPECT is a site-specific conjugation technology that targets select amino acid residues as a way of producing investigational homogeneous ADCs with defined drug-to-antibody ratios.  The Read mo...

‘Double Decker’ Antibody Technology Fights Cancer

NewsA new class of antibody-drug conjugates use a technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy.

#jobs #lifescience MedImmune: Intern – Antibody Discovery and Protein Engineering (FTC)

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MedImmune: Intern – Antibody Discovery and Protein Engineering (FTC) . ...

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M...

New Study: ‘Double Decker’ Antibody Technology Fights Cancer

JUPITER, Fla., Oct. 25, 2017 /PRNewswire-USNewswire/ — Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), us...

Cullinan Oncology and MAB Discovery Collaborate on Novel Antibody Therapeutics

US Cullinan Oncology, based in Cambridge, MA, and German MAB Discovery (MABD) announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD's discovery platform.

PubMed Articles [3934 Associated PubMed Articles listed on BioPortfolio]

Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.

Antibodies that target both group 1 and group 2 influenza A viruses are valuable for therapeutic and vaccine development, but only a few have been reported to date. Here, we describe a new VH1-69 anti...

Integration of Antibody Array Technology into Drug Discovery and Development.

Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widel...

Anti-Dll4 Antibody Inhibits the Differentiation of Th17 Cells in Asthmatic Mice.

T helper 17 (Th17) cells play an important role in allergic asthma, and the Notch ligand Delta-like ligand (Dll)4 has been reported to direct the differentiation of Th17 cells. In this study, experime...

Barcoded sequencing workflow for high throughput digitization of hybridoma antibody variable domain sequences.

Since the invention of Hybridoma technology by Milstein and Köhler in 1975, its application has greatly advanced the antibody discovery process. The technology enables both functional screening and l...

A Case of a Newborn With Blocked RhD Antigen and HDFN.

A group O RhD-negative pregnant patient with anti-D antibody at titer 1:2048 delivered a baby boy by cesarean section at 38 + 6 weeks gestational age. The neonate typed as group O, but D antigen was a...

Clinical Trials [6332 Associated Clinical Trials listed on BioPortfolio]

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.

Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in mothers and their infants at delivery to establish antibody levels associated with reductions in ...

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

This study looks at the body's immune responses to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P1 study. Blood will be drawn and evaluated for GBS antibody lev...

The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental Illness

The object is to develop a physical activity promotion program by applying social cognitive theory and wearable technology and evaluate its feasibility in people with MI Stage I: Accuracy...

Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds

The primary objective of this study is to detect differences in anti-S. aureus antibody assays (IgM, IgA, IgG and its subclasses) between (1) a group of patients with bacteremia due to a c...

Companies [3104 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

The Cambridge Group

The Cambridge Group ( is a strategy consulting firm focused on the development of growth strategies for Fortune 500 companies. For over 30 years, The Cambridge Gr...

More Information about "Cambridge Antibody Technology Group plc" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology Group plc news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Group plc Clinical Trials and PubMed Articles about Cambridge Antibody Technology Group plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Group plc Companies in our database. You can also find out about relevant Cambridge Antibody Technology Group plc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record